Matsuda-Nagasumi Kae

A Novel Antidiabetic Drug, Fasiglifam/TAK-875, Acts as an Ago-Allosteric Modulator of FFAR1

Chiori Yabuki, Hidetoshi Komatsu, Yoshiyuki Tsujihata et al. · PLoS ONE · 2013 · 91 citations · Full text

<scp>TAK</scp>‐875, a <scp>GPR</scp>40/<scp>FFAR</scp>1 agonist, in combination with metformin prevents progression of diabetes and <scp>β</scp>‐cell dysfunction in <scp>Z</scp>ucker diabetic fatty rats

Ryo Ito, Yoshiyuki Tsujihata, Matsuda-Nagasumi Kae et al. · British Journal of Pharmacology · 2013 · 36 citations · Full text

Lack of <scp>GPR40</scp> / <scp> FFAR ₁ </scp> does not induce diabetes even under insulin resistance condition

Matsuda-Nagasumi Kae, R. Takami‐Esaki, Kimihiko Iwachidow et al. · Diabetes Obesity and Metabolism · 2013 · 19 citations